2017 Innovative Research Grants
In 2017, Stand Up To Cancer announced the award of $7.5 million in Innovative Research Grants focused on immuno-oncology to 10 early-career scientists, in a program funded by a grant from Bristol-Myers Squibb Company (BMS), an SU2C Visionary Supporter. Over a three-year period, each investigator will receive up to $750,000.
“Immuno-oncology is one of the most exciting areas in cancer research today, and we believe these outstanding investigators have the potential to help take the field to the next level,” said William G. Kaelin, Jr., MD, professor at the Dana-Farber Cancer Institute and Harvard Medical School and chair of the SU2C Innovative Research Grants Committee (IRGC). “We want to see more patients benefitting from the science of immuno-oncology, so increasing the types of cancers for which treatment may be effective is critical. These researchers will bring new ideas and fresh energy to that effort.”
The ten 2017 SU2C IRG Recipients are:
Daniel A. Bachovchin, PhD, Memorial Sloan Kettering Cancer Center.
David M. Barrett, MD, PhD, Children’s Hospital of Philadelphia.
Gregory L. Beatty, MD, PhD, University of Pennsylvania.
Marie Bleakley, MD, PhD, Fred Hutchinson Cancer Research Center.
Michael D. Farwell, MD, University of Pennsylvania.
Rizwan Haq, MD, PhD, Dana-Farber Cancer Institute.
Meenakshi G. Hegde, MD, Baylor College of Medicine.
Marcela V. Maus, MD, PhD, Massachusetts General Hospital Cancer Center/Harvard Medical School.
Jennifer Wargo, MD, MMSc, The University of Texas MD Anderson Cancer Center.
John T. Wilson, PhD, Vanderbilt University.